TLSI SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

May 30, 2025

News

TYPE

HEADLINE

FILED AT

8-K

FDA Clears TriNav Advance, Expanding Pressure-Enabled Drug Delivery Portfolio for Distal-Vessel Liver Embolization Procedures

Sep 22, 2026

8-K

TriSalus Life Sciences Reports Second Quarter 2026 Financial Results

Aug 6, 2026

8-K

TriSalus Life Sciences, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 14, 2026

8-K

TriSalus Life Sciences Reports First Quarter 2026 Financial Results and Operational Updates

May 12, 2026

8-K

TriSalus Life Sciences Announces Executive Leadership Changes

Apr 29, 2026

8-K

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

Apr 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Feb 26, 2026

424B5

FIXED PRICE OFFERING | Offering amount: $40,000,010 | Shares: 9,756,100 | Price: $4.100 | Bank: Lake Street

Feb 20, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Lake Street

Feb 19, 2026

425

Form 425 - Prospectuses and communications, business combinations

Apr 30, 2025

424B3

UPDATED

Aug 15, 2024

424B3

UPDATED | OFFERING | Shares amount: 53,687,040 | Warrants amount: 5,933,333 | Warrants exercise price: $11.50

Aug 15, 2024

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 19, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 2, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 24, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Cox Bryan F. (Reporting)

Oct 7, 2026

Marshak Richard (Reporting)

Oct 7, 2026

Stevens Jennifer (Reporting)

Oct 7, 2026

Szela Mary T (Reporting)

Oct 7, 2026

SCHEDULE 13G/A

First Light Asset Management, LLC (Filed by)

Jul 7, 2026

Patience David (Reporting)

Jul 6, 2026

Other

TYPE

HEADLINE

FILED AT

TriSalus Life Sciences, Inc. TLSI · SEC Filings